Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Ann Thorac Surg. 2012 Oct;94(4):1295-301. doi: 10.1016/j.athoracsur.2012.05.031. Epub 2012 Jul 12.
We investigated the myocardial protective effect of a moderate-potassium cold blood cardioplegic solution (K+, 10 mmol/L) in pediatric cardiac surgery.
Sixty-eight pediatric patients with congenital heart disease and undergoing open heart surgery with cardiopulmonary bypass were randomly allocated to the high potassium (HP [K+, 20 mmol/L, n=31]) cold blood cardioplegia group or the moderate potassium (MP [K+, 10 mmol/L, n=37]) cold blood cardioplegia group. Heart arresting time, rhythm recovery time, mechanical ventilation time, inotropic drug use in the intensive care unit, perioperative serum cardiac troponin I concentrations, morbidities, and mortalities were compared between the two groups.
There were no differences in cardiopulmonary bypass time, aorta cross-clamping time, cardioplegia volume, lowest body temperature during cardiopulmonary bypass, total volume of cardioplegia delivered, hematocrit value, and fluid output during the operation between the two groups. However, there was a longer arresting time and a shorter rhythm recovery time in the MP group (35.6±2.4 s, and 30.8±3.1 s) when compared with that in the HP group (24.7±2.7 s, and 42.0±4.0 s, both p<0.05). The total mediastinal drainage volume, the length of stay in the intensive care unit, the postoperative inotropic drug use, and the postoperative hospital time were similar between the two groups, but the number of patients with a long postoperative mechanical ventilation time (>24 hours) in the MP group (6 of 36) was less than that in HP group (13 of 30; p<0.05). At 1 hour, 3 hours, and 6 hours after myocardium reperfusion, the serum concentration of cardiac troponin I significantly decreased in the MP group (in ng/mL: 15.18±3.57, 24.83±4.91, and 19.62±3.93, respectively) when compared with that in the HP group (in ng/mL: 32.67±5.31, 39.26±7.43, and 30.52±5.17, respectively, p<0.05).
The present study demonstrated that the M (10 mmol/L) cold blood cardioplegia formula is associated with better myocardial protective effects when compared with conventional HP cardioplegia in pediatric patients.
我们研究了低钾(K + ,10 mmol/L)冷血心脏停搏液在儿科心脏手术中的心肌保护作用。
68 例先天性心脏病患儿在体外循环下行心脏直视手术,随机分为高钾(HP [K + ,20 mmol/L ,n=31])冷血心脏停搏液组或低钾(MP [K + ,10 mmol/L ,n=37])冷血心脏停搏液组。比较两组心脏停搏时间、节律恢复时间、机械通气时间、重症监护室正性肌力药物使用、围术期血清心肌肌钙蛋白 I 浓度、并发症发生率和死亡率。
两组体外循环时间、主动脉阻断时间、停搏液量、体外循环期间最低体温、总停搏液量、血细胞比容值和术中液体输出量无差异。但 MP 组(35.6±2.4 s 和 30.8±3.1 s)的停搏时间较长,节律恢复时间较短(24.7±2.7 s 和 42.0±4.0 s,均 P<0.05)。两组总纵隔引流量、重症监护室停留时间、术后正性肌力药物使用和术后住院时间相似,但 MP 组(6 例)术后机械通气时间较长(>24 小时)的患者少于 HP 组(13 例;P<0.05)。再灌注后 1、3、6 小时,MP 组血清肌钙蛋白 I 浓度(ng/mL:15.18±3.57、24.83±4.91、19.62±3.93)较 HP 组(ng/mL:32.67±5.31、39.26±7.43、30.52±5.17)显著降低(均 P<0.05)。
与传统 HP 心脏停搏液相比,本研究表明在儿科患者中,M(10 mmol/L)冷血心脏停搏液配方具有更好的心肌保护作用。